Fecal Analysis in the Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing
Reimbursement criteria for fecal analysis and donor screening prior to fecal microbiota transplantation (FMT) for Blue Cross Blue Shield of New Mexico products; applicability may vary by product and plan documents govern when in conflict.
Document updated with literature review; Reimbursement Information unchanged; References revised.
Prior edits clarified that FMT testing applies to the donor sample and edited reimbursable and non-reimbursable test code lists across prior versions.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.